Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMPHOTERICIN B vs BUTENAFINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Aspergillosis,Blastomycosis,Candidiasis,Coccidioidomycosis,Cryptococcosis,Histoplasmosis,Mucormycosis,Sporotrichosis,Visceral leishmaniasis,Empiric therapy for febrile neutropenia,Meningitis (cryptococcal, coccidioidal)
Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
Terminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Primarily hepatic; exact enzymes not well characterized.
Not significantly metabolized; undergoes minimal hepatic metabolism via CYP enzymes (unknown specific isoforms).
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 60–70% bound to plasma proteins, predominantly albumin.
4–5 L/kg (extensive tissue binding, especially in liver, spleen, and lungs).
Not well characterized due to minimal systemic absorption; estimated volume of distribution is very low, consistent with extensive tissue binding or limited distribution.
IV: 100%; oral: <5%; topical: minimal systemic absorption.
Topical: Systemic bioavailability is less than 5% following topical administration; oral bioavailability has not been established as drug is not used systemically.
Acute kidney injury: consider dose reduction or switch to liposomal formulation. No specific GFR-based dose adjustments for conventional formulation; monitor renal function and electrolytes. For liposomal amphotericin B, no dosage adjustment required for renal impairment. Continuous renal replacement therapy: conventional amphotericin not recommended due to nephrotoxicity; liposomal preferred.
No dose adjustment required; negligible systemic absorption.
No specific Child-Pugh based dose adjustments. Use caution in hepatic impairment; monitor liver function tests. Dose adjustment not typically required.
No dose adjustment required; negligible systemic absorption.
Conventional amphotericin B: 0.25-1.5 mg/kg/day IV; initial test dose 0.1 mg/kg. Liposomal amphotericin B: 3-5 mg/kg/day IV. For neonates: 1 mg/kg/day. Maximum daily dose: 1.5 mg/kg for conventional, 5 mg/kg for liposomal.
≥12 years: same as adult; <12 years: safety and efficacy not established; use only if clearly needed.
Use with caution due to age-related renal function decline; monitor renal function and electrolyte levels carefully. Same dosing as adults; adjust for renal impairment if present. Lower doses may be considered based on clinical status.
No specific adjustment; same as adult dosing; monitor for skin irritation.
Amphotericin B should be used primarily for progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of fungal disease. It should be used under close medical supervision due to potential toxicity.
None.
Monitor renal function, electrolytes, and liver function; risk of nephrotoxicity, hypokalemia, hypomagnesemia, and infusion-related reactions; caution in patients with renal impairment and those receiving other nephrotoxic drugs.
For external use only.,Avoid contact with eyes, nose, mouth, and other mucous membranes.,Discontinue if irritation or sensitization occurs.,Not recommended for treatment of onychomycosis or scalp infections.
Hypersensitivity to amphotericin B or any component of the formulation; unless the potential benefit outweighs the risk.
Hypersensitivity to butenafine hydrochloride or any components of the formulation.
Avoid excessive salt intake; monitor for hypokalemia and hypomagnesemia. No specific food restrictions but maintain adequate hydration.
No clinically significant food interactions reported. Butenafine is applied topically and systemic absorption is minimal, so dietary restrictions are not required.
FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data suggest no increased risk of major malformations across all trimesters.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.
Excreted in breast milk in low levels; M/P ratio not established. Consideration of benefits vs risks; caution in nursing infants due to potential for oral absorption and adverse effects.
Unknown if excreted in human milk; M/P ratio not established. Use with caution in nursing mothers; consider benefits vs risks.
No specific dose adjustments recommended in pregnancy; standard dosing based on indication and patient weight. Pharmacokinetic changes in pregnancy (increased Vd, increased clearance) may theoretically require higher doses, but clinical data insufficient to recommend adjustment.
No dose adjustment required based on pharmacokinetic changes in pregnancy; topical application has minimal systemic absorption.
Premedicate with acetaminophen, diphenhydramine, and hydrocortisone to reduce infusion-related reactions. Monitor serum potassium and magnesium closely due to renal wasting. Use normal saline bolus before infusion to reduce nephrotoxicity. Lipid formulations allow higher doses with less nephrotoxicity. Amphotericin B deoxycholate is reserved for severe, refractory cases.
Butenafine hydrochloride is a benzylamine antifungal with fungicidal activity against dermatophytes (e.g., Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum) and yeasts (Malassezia spp.). It inhibits squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis. Applied once or twice daily for 1–4 weeks depending on indication. For tinea pedis (athlete's foot), treatment should extend 1 week beyond resolution to prevent recurrence. Avoid occlusion unless directed; may increase irritation. Contraindicated in hypersensitivity to any component. For severe or resistant cases, consider combination with keratolytics (e.g., salicylic acid) to enhance penetration.
You may experience fever, chills, and nausea during infusion; these are common and can be managed with premedications.,Report any signs of kidney problems such as decreased urine output, swelling in legs, or fatigue.,Avoid potassium and magnesium supplements unless prescribed, as levels may fluctuate.,This medication can cause low blood pressure during infusion; rise slowly from sitting or lying down.,Complete the full course even if you feel better to prevent the infection from returning.
Apply butenafine cream exactly as prescribed: clean and dry the affected area before application.,Use enough medication to cover the affected skin and a small margin of healthy surrounding skin.,Wash your hands after applying, unless treating the hands.,Do not cover the treated area with bandages or dressings unless instructed by your doctor.,Complete the full course of treatment even if symptoms improve, to prevent recurrence.,Notify your doctor if no improvement after 2–4 weeks or if irritation, redness, or blistering occurs.,Avoid contact with eyes, mouth, nose, or broken skin; if accidental contact occurs, rinse with water.,Do not use for conditions other than those prescribed; butenafine is for external use only.
"Efinaconazole, a triazole antifungal, inhibits fungal CYP450-dependent lanosterol 14α-demethylase, reducing ergosterol synthesis. Amphotericin B binds to ergosterol in fungal membranes, forming pores that cause cell death. Concomitant use may decrease Amphotericin B efficacy because efinaconazole depletes ergosterol, the target for Amphotericin B, potentially attenuating the polyene's antifungal activity, especially in systemic fungal infections."
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
"Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is primarily metabolized by CYP3A4 and CYP2C19. Butenafine, an antifungal agent, is also metabolized by CYP3A4. Concurrent use may inhibit the metabolism of butenafine, leading to increased systemic exposure and potential toxicity, including hepatotoxicity or QT prolongation."
"Ranolazine, an antianginal agent, inhibits CYP3A4 and CYP2D6, reducing the metabolism of Butenafine, an antifungal agent typically metabolized by these enzymes. This results in significantly elevated Butenafine serum concentrations, increasing the risk of systemic adverse effects such as hepatotoxicity and QT prolongation. Co-administration may lead to enhanced antifungal efficacy but also potential toxicity."
"Butenafine, an allylamine antifungal, inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis, leading to fungal cell death. Bepridil, a calcium channel blocker with class I antiarrhythmic properties, prolongs the QT interval by blocking cardiac potassium channels, increasing the risk of torsades de pointes. When combined, butenafine may further inhibit hERG potassium channels in cardiac myocytes, potentiating QT prolongation and elevating the risk of life-threatening ventricular arrhythmias, particularly in patients with preexisting QT prolongation or electrolyte abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMPHOTERICIN B vs BUTENAFINE HYDROCHLORIDE, answered by our medical review team.
AMPHOTERICIN B is a Antifungal that works by Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.. BUTENAFINE HYDROCHLORIDE is a Antifungal that works by Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMPHOTERICIN B and BUTENAFINE HYDROCHLORIDE depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMPHOTERICIN B is: 0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.. The standard adult dose of BUTENAFINE HYDROCHLORIDE is: 1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AMPHOTERICIN B and BUTENAFINE HYDROCHLORIDE. The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Butenafine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AMPHOTERICIN B is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data sug. BUTENAFINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.